BioThrax regulatory update

FDA approved an sBLA from Emergent for BioThrax to prevent disease following suspected or confirmed Bacillus anthracis exposure in patients ages 18-65. The vaccine is approved in the U.S. for pre-exposure prophylaxis of disease in people ages 18-65 at high risk of exposure. BioThrax contains cell-free filtrates of microaerophilic cultures of an avirulent, non-encapsulated strain of B. anthracis. ...